神州细胞(688520.SH)业绩快报：2025年净亏损5.53亿元

Core Viewpoint - Shenzhou Cell (688520.SH) reported a significant decline in revenue and a shift to net loss for the fiscal year 2025, primarily due to ongoing healthcare cost control policies and increased commercialization expenses [1] Financial Performance - The company achieved total operating revenue of 1.56 billion yuan, a year-on-year decrease of 37.91% [1] - The net profit attributable to the parent company was -553.29 million yuan, with a net profit excluding non-recurring gains and losses of -536.39 million yuan, marking a transition from profit to loss compared to the previous year [1] Factors Influencing Performance - The decline in revenue was significantly impacted by the deepening of healthcare cost control policies, leading to multiple price reductions of the core product, Anjia [1] - To facilitate market access and channel development for newly approved products, the company increased its commercialization investment, resulting in higher sales expenses [1] - The company continued to advance parallel research across multiple pipelines, with several projects in late-stage clinical research, maintaining high R&D expenditures that affected current profits, leading to a loss in 2025 [1]